Sonia Cohen

This study identifies genomic subtypes and immune features of mucosal melanoma, linking CD163+ macrophages to immune resistance and suggesting TIM-3 blockade as a therapeutic target.

The paper shows that removing tumor-draining lymph nodes does not impair immune checkpoint blockade response, as distant lymph nodes compensate for the loss.

The paper introduces DIGEST, an ultrasensitive digital immunoassay for quantifying host proteins in fecal samples, demonstrating its utility in tracking immune dynamics and predicting disease outcomes.

This study shows that breast tumors impair antigen presentation in local lymph nodes, which can be overcome by delivering IL1β or adjuvants to distant lymph nodes, improving anti-cancer immune responses.

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

This paper describes a designed IL-21 mimic, 21h10, which shows potent antitumor activity in multiple models and reduces toxicity through TNF blockade.

This study shows oncolytic virus therapy primarily elicits anti-virus T cell responses rather than anti-cancer responses, explaining limited clinical efficacy in metastatic disease.

The paper uses buoyant mass to identify distinct T cell states that predict response to immune checkpoint therapy in melanoma patients.